Skip to main content

Immunosuppression — Perioperative Management

Immunosuppressed patients — including solid organ transplant recipients, patients on biologics for autoimmune disease, and those on chronic corticosteroids — require careful perioperative planning. Concerns include increased infection risk, impaired wound healing, allograft rejection risk with medication interruption, and drug interactions with anesthetics. GU reconstructive procedures in transplant recipients (e.g., ureteral reconstruction, renal autotransplantation) represent a particularly high-complexity scenario.

Solid Organ Transplant Recipients​

Reconstructive urology intersects most often with kidney transplantation: ureteral leak / stricture, transplant ureteral reconstruction, post-transplant fistula, VCA, and benign reconstruction in patients carrying chronic immunosuppression. Standard maintenance immunosuppression commonly combines tacrolimus, an antimetabolite such as mycophenolate, and low-dose glucocorticoids; abrupt interruption can precipitate rejection, while excessive immunosuppression worsens infection and wound failure.[1]

Practical perioperative rules:

  • Coordinate medication changes with the transplant team before elective reconstruction.
  • Do not stop calcineurin inhibitors casually; check troughs when bowel dysfunction, interacting antibiotics, or renal injury changes exposure.
  • Temporarily reducing mycophenolate during active infection or fistula management may be reasonable, but early post-transplant reduction carries rejection risk.[2]
  • Hold or avoid mTOR inhibitors such as sirolimus / everolimus when major wound healing is required.
  • Treat sepsis first: drainage, diversion, antibiotics, and delayed reconstruction are safer than definitive repair in an uncontrolled immunosuppressed field.

Biologic Agents — Perioperative Holding​

For autoimmune biologics, the reconstructive question is usually whether the operation is clean, clean-contaminated, or frankly contaminated, and whether the disease will flare if therapy is held. The site does not yet maintain a drug-by-drug biologic table, so use the local specialist's protocol and document the plan.

General principles:

  • Avoid elective prosthetic implantation or large flap/graft reconstruction during uncontrolled systemic inflammation.
  • Time elective surgery near the end of the biologic dosing interval when feasible.
  • Restart only after early wound healing is secure and there is no uncontrolled infection.
  • For Crohn-related rectovaginal or enterourinary fistula, drain sepsis and place setons before escalating immunosuppression.

Infection Risk Mitigation​

  • Screen for active UTI, skin infection, cellulitis, fistula-associated abscess, and infected hardware.
  • Use culture-directed antibiotics when reconstruction is being performed in a chronically colonized system.
  • Drain urinomas, abscesses, and infected collections before definitive reconstruction.
  • In transplant ureteral leak / fistula, urinary diversion with nephrostomy and drainage is often more important than immediate repair.
  • Minimize prosthetic placement in actively infected or heavily immunosuppressed fields.

Wound Healing Considerations​

Immunosuppression changes the threshold for choosing vascularized tissue. In radiated, infected, or transplant fields, interposition with omentum, gracilis, Martius, VRAM, or other healthy tissue may be the difference between repair and recurrence. mTOR inhibitors are particularly relevant because of their wound-healing signal; corticosteroids add hyperglycemia, infection, and collagen-formation concerns, but they may also be non-negotiable for graft survival.

For corticosteroid-specific stress dosing, antiemetic use, transplant rejection treatment, and steroid withdrawal data, see Corticosteroids. For transplant urinary fistula reconstruction, see Post-Kidney-Transplant Urinary Fistula / Leak.

References​

1. Hariharan S, Israni AK, Danovitch G. "Long-term survival after kidney transplantation." N Engl J Med. 2021;385(8):729-743. doi:10.1056/NEJMra2014530

2. Yang B, Ye Q, Huang C, Ding X. "Impact of infection-related immunosuppressant reduction on kidney transplant outcomes: a retrospective study." Transpl Int. 2023;36:11802. doi:10.3389/ti.2023.11802